|
Gene: GLI1 |
Gene summary for GLI1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | GLI1 | Gene ID | 2735 |
Gene name | GLI family zinc finger 1 | |
Gene Alias | GLI | |
Cytomap | 12q13.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B4DNF7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2735 | GLI1 | ATC13 | Human | Thyroid | ATC | 4.60e-30 | 6.01e-01 | 0.34 |
2735 | GLI1 | ATC5 | Human | Thyroid | ATC | 6.62e-35 | 6.51e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001605525 | Thyroid | ATC | Wnt signaling pathway | 234/6293 | 444/18723 | 4.64e-17 | 4.31e-15 | 234 |
GO:019873825 | Thyroid | ATC | cell-cell signaling by wnt | 234/6293 | 446/18723 | 9.26e-17 | 8.25e-15 | 234 |
GO:003011125 | Thyroid | ATC | regulation of Wnt signaling pathway | 177/6293 | 328/18723 | 1.83e-14 | 1.05e-12 | 177 |
GO:000150332 | Thyroid | ATC | ossification | 206/6293 | 408/18723 | 9.23e-13 | 3.95e-11 | 206 |
GO:006082825 | Thyroid | ATC | regulation of canonical Wnt signaling pathway | 134/6293 | 253/18723 | 1.49e-10 | 4.56e-09 | 134 |
GO:004873233 | Thyroid | ATC | gland development | 210/6293 | 436/18723 | 1.50e-10 | 4.59e-09 | 210 |
GO:006007025 | Thyroid | ATC | canonical Wnt signaling pathway | 154/6293 | 303/18723 | 3.68e-10 | 1.02e-08 | 154 |
GO:004578719 | Thyroid | ATC | positive regulation of cell cycle | 158/6293 | 313/18723 | 4.18e-10 | 1.14e-08 | 158 |
GO:000164932 | Thyroid | ATC | osteoblast differentiation | 122/6293 | 229/18723 | 6.04e-10 | 1.60e-08 | 122 |
GO:000188927 | Thyroid | ATC | liver development | 85/6293 | 147/18723 | 1.37e-09 | 3.43e-08 | 85 |
GO:006100827 | Thyroid | ATC | hepaticobiliary system development | 86/6293 | 150/18723 | 1.96e-09 | 4.78e-08 | 86 |
GO:190198715 | Thyroid | ATC | regulation of cell cycle phase transition | 187/6293 | 390/18723 | 2.36e-09 | 5.61e-08 | 187 |
GO:000165522 | Thyroid | ATC | urogenital system development | 164/6293 | 338/18723 | 7.92e-09 | 1.70e-07 | 164 |
GO:004484316 | Thyroid | ATC | cell cycle G1/S phase transition | 119/6293 | 241/18723 | 2.68e-07 | 4.10e-06 | 119 |
GO:006145827 | Thyroid | ATC | reproductive system development | 193/6293 | 427/18723 | 3.32e-07 | 4.92e-06 | 193 |
GO:003032321 | Thyroid | ATC | respiratory tube development | 93/6293 | 181/18723 | 5.67e-07 | 8.02e-06 | 93 |
GO:004860825 | Thyroid | ATC | reproductive structure development | 190/6293 | 424/18723 | 8.40e-07 | 1.11e-05 | 190 |
GO:009006817 | Thyroid | ATC | positive regulation of cell cycle process | 115/6293 | 236/18723 | 9.87e-07 | 1.29e-05 | 115 |
GO:006053724 | Thyroid | ATC | muscle tissue development | 181/6293 | 403/18723 | 1.27e-06 | 1.62e-05 | 181 |
GO:003032421 | Thyroid | ATC | lung development | 90/6293 | 177/18723 | 1.53e-06 | 1.88e-05 | 90 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GLI1 | insertion | Frame_Shift_Ins | novel | c.1601_1602insC | p.Val537SerfsTer4 | p.V537Sfs*4 | P08151 | protein_coding | TCGA-CV-7253-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | ||
GLI1 | SNV | Missense_Mutation | c.2207N>T | p.Glu736Val | p.E736V | P08151 | protein_coding | tolerated(0.06) | benign(0.039) | TCGA-EJ-5525-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD | |
GLI1 | SNV | Missense_Mutation | rs201845227 | c.1669N>T | p.Arg557Cys | p.R557C | P08151 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-G9-6369-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD |
GLI1 | SNV | Missense_Mutation | novel | c.1690C>T | p.Pro564Ser | p.P564S | P08151 | protein_coding | deleterious(0.04) | probably_damaging(0.941) | TCGA-VN-A88I-01 | Prostate | prostate adenocarcinoma | Male | <65 | 8 | Unknown | Unknown | SD |
GLI1 | SNV | Missense_Mutation | rs759027001 | c.1487G>A | p.Arg496His | p.R496H | P08151 | protein_coding | tolerated(0.66) | benign(0.001) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
GLI1 | SNV | Missense_Mutation | c.1628N>A | p.Ser543Asn | p.S543N | P08151 | protein_coding | tolerated(0.47) | benign(0.15) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GLI1 | SNV | Missense_Mutation | c.2852N>A | p.Gly951Asp | p.G951D | P08151 | protein_coding | tolerated_low_confidence(0.05) | probably_damaging(0.999) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GLI1 | SNV | Missense_Mutation | c.1978N>A | p.Leu660Met | p.L660M | P08151 | protein_coding | tolerated(0.34) | probably_damaging(0.996) | TCGA-CD-8536-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | epirubicin | CR | |
GLI1 | SNV | Missense_Mutation | c.250N>C | p.Ser84Pro | p.S84P | P08151 | protein_coding | deleterious(0) | possibly_damaging(0.564) | TCGA-CG-4465-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD | |
GLI1 | SNV | Missense_Mutation | rs373249560 | c.941N>A | p.Arg314His | p.R314H | P08151 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CG-5726-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2735 | GLI1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | Isoflavone derivative 2 | |||
2735 | GLI1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | Isoflavone derivative 3 | |||
2735 | GLI1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | Isoflavone derivative 1 | |||
2735 | GLI1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | Imidazo bicyclic iminium derivative 2 | |||
2735 | GLI1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | 4-METHYLENE-5BETA-HYDROPEROXYOVATODIOLIDE | CHEMBL471694 | 26178912 | |
2735 | GLI1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | Isoflavone derivative 9 | |||
2735 | GLI1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | 4ALPHA-HYDROPEROXY-5-ENOVATODIOLIDE | CHEMBL512307 | 26178912 | |
2735 | GLI1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | PMID26666870-Compound-16 | |||
2735 | GLI1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | BETULINIC ACID | BETULINIC ACID | 18842418 | |
2735 | GLI1 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | Isoflavone derivative 7 |
Page: 1 2 |